CRESCENT BIOPHARMA, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
a. On February 24, 2026, we provided notice to Paragon of our intention to terminate the ADC Paragon Option Agreement, which covers the product candidate formerly referred to as CR-003, in light of our having in-licensed SKB105 from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, which we intend to develop as CR-003. We expect that the agreement will terminate on or about March 26, 2026. See Part I, Item 1, “Business” for additional information regarding the parties to the agreement, the material terms, and the warrants issued to Parascent in connection with the termination. Other than the warrant issuance, there are no early termination penalties associated with the termination.
b. During the fourth quarter of 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any “Rule 10b5-1 trading arrangement” and/or “non-Rule 10b5-1 trading arrangement,” in each case, as defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.